Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results
Christine D. Palmer(AstraZeneca (United States)), Karin Jooss(Unknown), Benny Johnson(The University of Texas MD Anderson Cancer Center), Aaron Yang, Mojca Škoberne, Ciaran D. Scallan, Martina Marrali, Desiree Schenk, Jason R. Jaroslavsky, Andrew M. Allen, Raphaël F. Rousseau, Meghan G. Hart, Charles G. Drake(Columbia University Irving Medical Center), Shawn Chan, Daniel Navarro-Gomez, Alexander I. Spira(Virginia Cancer Specialists), Andrew R. Ferguson, Benjamin Solomon(Peter MacCallum Cancer Centre), Kiara Taquechel, Adrienne C. Greene, Charmaine N. Nganje, Leonid Gitlin, David P. Carbone(Vanderbilt University), Gijsbert M. Grotenbreg, Daniel H. Ahn(Mayo Clinic Hospital), Renee L. Greer, Rita Zhou, Sue‐Jean Hong, Lauren D. Kraemer, Chih‐Yi Liao(University of Chicago), Sonia Kounlavouth, Roman Yelensky(National Vaccine and Serum Institute), Brian S. Henick(NewYork–Presbyterian Hospital), Matthew J. Davis, Elizabeth Maloney, Daniel V.T. Catenacci(University of Chicago), Minh Duc Cao, Wade Blair, Sameek Roychowdhury(The Ohio State University Wexner Medical Center), Lindsey Smith(Massachusetts Institute of Technology), Kyounghwa Bae, Amit Mahipal(Dana-Farber Cancer Institute), Steve Maron(Memorial Sloan Kettering Cancer Center), Amy Rappaport(Joint BioEnergy Institute)
Cited by 225
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k